Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accumulated Expenses (2018 - 2025)

Bioadaptives' Accumulated Expenses history spans 8 years, with the latest figure at $215973.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 25.93% to $215973.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $215973.0, a 25.93% increase, with the full-year FY2025 number at $215973.0, up 25.93% from a year prior.
  • Accumulated Expenses hit $215973.0 in Q4 2025 for Bioadaptives, up from $203997.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for BDPT hit a ceiling of $215973.0 in Q4 2025 and a floor of $1003.0 in Q1 2022.
  • Historically, Accumulated Expenses has averaged $96678.4 across 5 years, with a median of $126294.0 in 2023.
  • Biggest five-year swings in Accumulated Expenses: crashed 90.85% in 2022 and later surged 14223.16% in 2024.
  • Tracing BDPT's Accumulated Expenses over 5 years: stood at $6200.0 in 2021, then skyrocketed by 1527.73% to $100919.0 in 2022, then skyrocketed by 36.7% to $137955.0 in 2023, then increased by 24.32% to $171507.0 in 2024, then grew by 25.93% to $215973.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BDPT at $215973.0 in Q4 2025, $203997.0 in Q3 2025, and $190167.0 in Q2 2025.